Zobrazeno 1 - 10
of 651
pro vyhledávání: '"nafamostat mesilate"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mahoko Ikeda, Shu Okugawa, Kosuke Kashiwabara, Takashi Moritoyo, Yoshiaki Kanno, Daisuke Jubishi, Hideki Hashimoto, Koh Okamoto, Kenji Tsushima, Yasuki Uchida, Takahiro Mitsumura, Hidetoshi Igari, Takeya Tsutsumi, Hideki Araoka, Kazuhiro Yatera, Yoshihiro Yamamoto, Yuki Nakamura, Amato Otani, Marie Yamashita, Yuji Wakimoto, Takayuki Shinohara, Maho Adachi-Katayama, Tatsunori Oyabu, Aoi Kanematsu, Sohei Harada, Yuichiro Takeshita, Yasutaka Nakano, Yasunari Miyazaki, Seiichiro Sakao, Makoto Saito, Sho Ogura, Kei Yamasaki, Hitoshi Kawasuji, Osamu Hataji, Jun-Ichiro Inoue, Yasuyuki Seto, Kyoji Moriya
Publikováno v:
International Journal of Infectious Diseases, Vol 128, Iss , Pp 355-363 (2023)
Objectives: To evaluate the efficacy and safety of nafamostat combined with favipiravir for the treatment of COVID-19. Methods: We conducted a multicenter, randomized, single-blind, placebo-controlled, parallel assignment study in hospitalized patien
Externí odkaz:
https://doaj.org/article/b44f924622ed47a1904be3da3e84d112
Autor:
Yao Lin, Yiming Shao, Yuchun Liu, Ruoxuan Yang, Shuanglin Liao, Shuai Yang, Mingwei Xu, Junbing He
Publikováno v:
Renal Failure, Vol 44, Iss 1, Pp 1263-1279 (2022)
Background Nafamostat mesilate (NM), a broad-spectrum and potent serine protease inhibitor, can be used as an anticoagulant during extracorporeal circulation, as well as a promising drug effective against coronavirus disease 2019 (COVID-19). We condu
Externí odkaz:
https://doaj.org/article/4e06a203142c45209ce0cf1b3d629060
Autor:
Jae Ha Lee, Jin Han Park, Ji Hoon Jang, Se Hun Kim, Sung Yong Hong, Woon Heo, Dong-Hwan Lee, Hye Sook Choi, Ki Hoon Kim, Hang-Jea Jang
Publikováno v:
Acute and Critical Care, Vol 37, Iss 2, Pp 177-184 (2022)
Background Anticoagulation during extracorporeal membrane oxygenation (ECMO) usually is required to prevent thrombosis. The aim of this study was to investigate the usefulness of nafamostat mesilate (NM) as a regional anticoagulant during veno-arteri
Externí odkaz:
https://doaj.org/article/88647dbbf05743249fa1efd6d66f4163
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-9 (2021)
Abstract Background This study is designed to evaluate the main hypothesis that nafamostat mesilate with standard therapy improves the severity and mortality rate in patients with COVID-19 pneumonia. Methods We conduct a randomized, open type, multi-
Externí odkaz:
https://doaj.org/article/72069f30a36449dbb9ccdebb6b130649
Publikováno v:
JA Clinical Reports, Vol 6, Iss 1, Pp 1-4 (2020)
Abstract Background Heparin-induced thrombocytopenia type II (HIT II) is a rare, immune-mediated complication of heparin therapy and can cause life-threatening thromboembolism. However, perioperative anticoagulation therapy for patients with a compli
Externí odkaz:
https://doaj.org/article/6903dc99888d440d82b0805470f09fcb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sergey V Zhuravel, Oleg K Khmelnitskiy, Oleg O Burlaka, Alexey I Gritsan, Boris M Goloshchekin, Seieun Kim, Ka Young Hong
Publikováno v:
EClinicalMedicine, Vol 41, Iss , Pp 101169- (2021)
ABSTRACT: Background: Nafamostat, a serine protease inhibitor, has been used for the treatment of disseminated intravascular coagulation and pancreatitis. In vitro studies and clinical reports suggest its beneficial effect in the treatment of COVID-1
Externí odkaz:
https://doaj.org/article/14afed7bb9184236b81398a75b034ae3
Publikováno v:
Renal Replacement Therapy, Vol 5, Iss 1, Pp 1-6 (2019)
Abstract Background A spontaneous iliopsoas muscle hematoma is relatively rare and often associated with abnormal coagulation. Nafamostat mesilate is an anticoagulant agent that is sometimes used to treat hemodialysis patients at high risk of bleedin
Externí odkaz:
https://doaj.org/article/9b2196dda8a749ab8eff381176eba379
Autor:
Kent Doi, Osamu Nishida, Takashi Shigematsu, Tomohito Sadahiro, Noritomo Itami, Kunitoshi Iseki, Yukio Yuzawa, Hirokazu Okada, Daisuke Koya, Hideyasu Kiyomoto, Yugo Shibagaki, Kenichi Matsuda, Akihiko Kato, Terumasa Hayashi, Tomonari Ogawa, Tatsuo Tsukamoto, Eisei Noiri, Shigeo Negi, Koichi Kamei, Hirotsugu Kitayama, Naoki Kashihara, Toshiki Moriyama, Yoshio Terada, The Japanese Clinical Practice Guideline for Acute Kidney Injury 2016 Committee
Publikováno v:
Renal Replacement Therapy, Vol 4, Iss 1, Pp 1-55 (2018)
Abstract Acute kidney injury (AKI) is a syndrome which has a broad range of etiologic factors depending on different clinical settings. Because AKI has significant impacts on prognosis in any clinical settings, early detection and intervention are ne
Externí odkaz:
https://doaj.org/article/06c24baa62a948c7ad106b9709900e1d